EA201691695A1 - Терапевтические композиции, содержащие рилпивирин hcl и тенофовира дизопроксилфумарат - Google Patents

Терапевтические композиции, содержащие рилпивирин hcl и тенофовира дизопроксилфумарат

Info

Publication number
EA201691695A1
EA201691695A1 EA201691695A EA201691695A EA201691695A1 EA 201691695 A1 EA201691695 A1 EA 201691695A1 EA 201691695 A EA201691695 A EA 201691695A EA 201691695 A EA201691695 A EA 201691695A EA 201691695 A1 EA201691695 A1 EA 201691695A1
Authority
EA
Eurasian Patent Office
Prior art keywords
rilpivirin
tenofovira
hcl
compositions containing
therapeutic compositions
Prior art date
Application number
EA201691695A
Other languages
English (en)
Inventor
Реза Олияй
Лорен Вайсер
Марк Меннинг
Original Assignee
Джилид Сайэнс, Инк.
Дженссен Сайенсиз Айэлэнд Юс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45094284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201691695(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Джилид Сайэнс, Инк., Дженссен Сайенсиз Айэлэнд Юс filed Critical Джилид Сайэнс, Инк.
Publication of EA201691695A1 publication Critical patent/EA201691695A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

В настоящем изобретении предложены многослойные таблетки, содержащие гидрохлорид рилпивирина, эмтрицитабин и тенофовира дизопроксилфумарат. Указанные таблетки подходят для лечения ВИЧ.
EA201691695A 2010-11-19 2011-11-18 Терапевтические композиции, содержащие рилпивирин hcl и тенофовира дизопроксилфумарат EA201691695A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41560010P 2010-11-19 2010-11-19

Publications (1)

Publication Number Publication Date
EA201691695A1 true EA201691695A1 (ru) 2017-11-30

Family

ID=45094284

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201390651A EA025852B1 (ru) 2010-11-19 2011-11-18 ТЕРАПЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ РИЛПИВИРИН HCl И ТЕНОФОВИРА ДИЗОПРОКСИЛФУМАРАТ
EA201691695A EA201691695A1 (ru) 2010-11-19 2011-11-18 Терапевтические композиции, содержащие рилпивирин hcl и тенофовира дизопроксилфумарат

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201390651A EA025852B1 (ru) 2010-11-19 2011-11-18 ТЕРАПЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ РИЛПИВИРИН HCl И ТЕНОФОВИРА ДИЗОПРОКСИЛФУМАРАТ

Country Status (35)

Country Link
US (1) US10857102B2 (ru)
EP (2) EP2826466A1 (ru)
JP (2) JP2014500261A (ru)
KR (1) KR101923103B1 (ru)
CN (2) CN103491948B (ru)
AP (1) AP3816A (ru)
AR (2) AR084500A1 (ru)
AU (3) AU2011329642B2 (ru)
BR (1) BR112013012245B1 (ru)
CA (1) CA2818097C (ru)
CL (1) CL2013001402A1 (ru)
CO (1) CO6761300A2 (ru)
CR (1) CR20130293A (ru)
DK (1) DK2640362T4 (ru)
EA (2) EA025852B1 (ru)
EC (2) ECSP13012700A (ru)
ES (1) ES2524408T5 (ru)
HK (2) HK1190064A1 (ru)
HR (1) HRP20140946T1 (ru)
IL (1) IL226300B (ru)
MA (1) MA34735B1 (ru)
ME (1) ME01980B (ru)
MX (1) MX347512B (ru)
MY (1) MY185604A (ru)
NZ (1) NZ610729A (ru)
PE (3) PE20140163A1 (ru)
PL (1) PL2640362T5 (ru)
PT (1) PT2640362E (ru)
RS (1) RS53691B1 (ru)
SG (3) SG10201912527XA (ru)
SM (1) SMT201400150B (ru)
TW (1) TWI556840B (ru)
UA (1) UA114075C2 (ru)
WO (1) WO2012068535A1 (ru)
ZA (1) ZA201304481B (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105596356A (zh) 2003-01-14 2016-05-25 吉里德科学公司 用于联合抗病毒治疗的组合物和方法
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
CN103491948B (zh) 2010-11-19 2016-11-02 吉利德科学公司 包含利匹韦林HCl和富马酸替诺福韦酯的治疗组合物
MX336627B (es) 2011-08-16 2016-01-26 Gilead Sciences Inc Hemifumarato de tenofovir alafenamida.
CA2779052A1 (en) * 2012-05-31 2013-11-30 Pharmascience Inc. Pharmaceutical composition of entecavir and process of manufacturing
PT2822954E (pt) 2012-12-21 2016-06-16 Gilead Sciences Inc Compostos carbamoilpiridona policíclicos e seu uso farmacêutico
WO2015014737A1 (en) * 2013-07-29 2015-02-05 Sanovel Ilac Sanayi Ve Ticaret A.S. Multilayer tablet formulations comprising tenofovir and entecavir
CZ2013985A3 (cs) * 2013-12-09 2015-06-17 Zentiva, K.S. Stabilní farmaceutická kompozice obsahující tenofovir disoproxil fumarát
WO2015152433A1 (en) * 2014-03-31 2015-10-08 Hanmi Pharm. Co., Ltd. Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
KR20170123308A (ko) 2014-12-26 2017-11-07 에모리 유니버시티 Ｎ4-하이드록시시티딘, 이와 관련된 유도체 및 이의 항 바이러스적 용도
US9839212B2 (en) 2015-04-16 2017-12-12 Bio-Lab, Inc. Multicomponent and multilayer compacted tablets
KR20170003063A (ko) * 2015-06-30 2017-01-09 한미약품 주식회사 테노포비어 디소프록실 함유 경구용 고형제제 및 그 제조방법
CA2921336A1 (en) * 2015-06-30 2016-12-30 Gilead Sciences, Inc. Pharmaceutical formulations
ES2757560T3 (es) * 2015-11-09 2020-04-29 Gilead Sciences Inc Composiciones terapéuticas para el tratamiento del virus de la inmunodeficiencia humana
EP3439639A1 (en) * 2016-04-08 2019-02-13 Shionogi & Co., Ltd. Stabilized solid dosage form
TR201617448A2 (tr) * 2016-11-29 2018-06-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Tenofovi̇r ve emtri̇si̇tabi̇n i̇çeren kati oral farmasöti̇k bi̇leşi̇mler
US10561614B2 (en) * 2017-01-27 2020-02-18 Steerlife India Private Limited Tenofovir granules
BR112019027915A2 (pt) * 2017-06-30 2020-07-14 Viiv Healthcare Company composição de carboidrato de baixo teor glicêmico disponível, composição nutricional líquida, e, uso de uma composição de carboidrato
US11331331B2 (en) 2017-12-07 2022-05-17 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
JP2022538338A (ja) * 2019-07-03 2022-09-01 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー リルピビリンを用いて小児患者におけるｈｉｖを治療する方法
CN112137981A (zh) * 2020-11-02 2020-12-29 成都晶富医药科技有限公司 富马酸丙酚替诺福韦片及其制备工艺

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ241625A (en) 1991-02-22 1996-03-26 Univ Emory 1,3-oxathiolane derivatives, anti-viral compositions containing such and method of resolving racemic mixture of enantiomers
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en) * 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
AU2002359518A1 (en) 2001-11-27 2003-06-10 Bristol-Myers Squibb Company Efavirenz tablet formulation having unique biopharmaceutical characteristics
CN105596356A (zh) 2003-01-14 2016-05-25 吉里德科学公司 用于联合抗病毒治疗的组合物和方法
PT1632232E (pt) 2004-09-02 2011-08-02 Janssen Pharmaceutica Nv Sal de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]- 2-pirimidinil]amino]benzonitrilo
CA2577288C (en) 2004-09-02 2010-11-30 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
TWI375560B (en) * 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
AU2006304180A1 (en) 2005-10-14 2007-04-26 Microdose Therapeutx, Inc. Pharmaceutical packaging of an oral dosage combination
AP2008004533A0 (en) 2005-12-14 2008-08-31 Cipla Ltd Pharmaceutical combination
DK2487166T3 (en) * 2007-02-23 2017-02-20 Gilead Sciences Inc Modulators of the pharmacokinetic properties of therapeutics
WO2008140461A1 (en) 2007-05-16 2008-11-20 Fmc Corporation Solid form
US20080286344A1 (en) 2007-05-16 2008-11-20 Olivia Darmuzey Solid form
CN101778855A (zh) * 2007-05-22 2010-07-14 阿尔迪默菲克斯技术有限责任公司 替诺福韦酯半富马酸共晶体
WO2009037449A1 (en) 2007-09-18 2009-03-26 Cipla Limited Solid pharmaceutical compositions comprising one or more herpes virus inhibitors and one or more reverse transcriptase inhibitors
WO2009106960A2 (en) 2008-02-27 2009-09-03 Aurobindo Pharma Limited Stable compositions of lamivudine, tenofovir and efavirenz
PL2296633T3 (pl) 2008-05-02 2016-03-31 Gilead Sciences Inc Zastosowanie cząsteczek stałych nośników dla udoskonalenia przetwarzalności środka farmaceutycznego
JP5611242B2 (ja) 2009-02-06 2014-10-22 ギリアード サイエンシーズ， インコーポレイテッド 併用治療のための錠剤
ES2730805T3 (es) 2009-09-21 2019-11-12 Gilead Sciences Inc Análogos de carba-nucleósido sustituido por 2'-fluoro para el tratamiento antiviral
WO2011077100A1 (en) 2009-12-24 2011-06-30 Cipla Limited Antiretroviral composition
CN103491948B (zh) 2010-11-19 2016-11-02 吉利德科学公司 包含利匹韦林HCl和富马酸替诺福韦酯的治疗组合物

Also Published As

Publication number Publication date
CN103491948B (zh) 2016-11-02
CO6761300A2 (es) 2013-09-30
AP2013006931A0 (en) 2013-06-30
SG10201509521WA (en) 2015-12-30
PL2640362T3 (pl) 2015-03-31
PE20170521A1 (es) 2017-05-27
CN103491948A (zh) 2014-01-01
BR112013012245B1 (pt) 2022-09-27
AR123409A2 (es) 2022-11-30
BR112013012245A2 (pt) 2016-08-09
AP3816A (en) 2016-09-30
TW201238612A (en) 2012-10-01
AU2018202635A1 (en) 2018-05-10
SMT201400150B (it) 2015-01-15
NZ610729A (en) 2015-10-30
IL226300B (en) 2019-05-30
UA114075C2 (xx) 2017-04-25
SG190333A1 (en) 2013-06-28
EA201390651A1 (ru) 2013-11-29
PE20140163A1 (es) 2014-02-08
JP6138851B2 (ja) 2017-05-31
ME01980B (me) 2015-05-20
MX347512B (es) 2017-04-28
AU2016208417A1 (en) 2016-08-18
SG10201912527XA (en) 2020-02-27
US20130243857A1 (en) 2013-09-19
AR084500A1 (es) 2013-05-22
WO2012068535A1 (en) 2012-05-24
MY185604A (en) 2021-05-25
ES2524408T3 (es) 2014-12-09
HK1206592A1 (en) 2016-01-15
CA2818097C (en) 2019-07-30
PL2640362T5 (pl) 2022-05-02
DK2640362T3 (en) 2014-12-01
ECSP13012700A (es) 2013-08-30
PT2640362E (pt) 2014-11-28
DK2640362T4 (da) 2022-03-07
ECSP19078196A (es) 2019-11-30
JP2015131853A (ja) 2015-07-23
HRP20140946T1 (hr) 2015-02-13
EP2640362B2 (en) 2021-12-01
PE20211657A1 (es) 2021-08-24
CL2013001402A1 (es) 2013-12-27
AU2016208417B2 (en) 2018-04-05
EP2826466A1 (en) 2015-01-21
KR20140037799A (ko) 2014-03-27
AU2011329642A1 (en) 2013-05-02
JP2014500261A (ja) 2014-01-09
CA2818097A1 (en) 2012-05-24
ZA201304481B (en) 2022-03-30
HK1190064A1 (en) 2014-06-27
KR101923103B1 (ko) 2018-11-28
US10857102B2 (en) 2020-12-08
MA34735B1 (fr) 2013-12-03
ES2524408T5 (es) 2022-04-25
CR20130293A (es) 2013-10-03
TWI556840B (zh) 2016-11-11
EP2640362A1 (en) 2013-09-25
AU2011329642B2 (en) 2016-08-11
CN106511357A (zh) 2017-03-22
EA025852B1 (ru) 2017-02-28
RS53691B1 (en) 2015-04-30
MX2013005669A (es) 2013-11-04
EP2640362B1 (en) 2014-09-10

Similar Documents

Publication Publication Date Title
EA201691695A1 (ru) Терапевтические композиции, содержащие рилпивирин hcl и тенофовира дизопроксилфумарат
ZA202202711B (en) Sustained-release dosage forms of ruxolitinib
EA201590165A1 (ru) Сдерживающие злоупотребление фармацевтические композиции для контролируемого высвобождения
EA202092456A3 (ru) Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака
EA201500314A1 (ru) Лекарственные формы энзалутамида
EA201290322A1 (ru) Лечение желудочно-кишечных расстройств
TW201129382A (en) Antibody formulation and therapeutic regimens
EA201201263A1 (ru) Фармацевтическая композиция, содержащая этексилат дабигатрана
CY1124331T1 (el) Αυξημενη βιοδιαθεσιμοτητα δραστικης ουσιας σε θεραπεια ναλτρεξονης
EA201291211A1 (ru) Фармацевтические композиции, содержащие гидроморфон и налоксон
CY1118074T1 (el) Ανθελονοσιακοι παραγοντες
EA201171414A1 (ru) Ингибиторы белков семейства iap
IN2013CH05288A (ru)
EA201500368A1 (ru) Фармацевтическая композиция 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей для лечения кардиоваскулярной патологии
TR201100151A2 (tr) İbandronate formülasyonu.
CY1118255T1 (el) Υποκατεστημενα 6-αμινο-νικοτιναμιδια τα οποια φερουν μια ομαδα που περιεχει οη ως διαμορφωτες των kcnq2/3
CY1116115T1 (el) Θεραπευτικες συνθεσεις οι οποιες αποτελουνται απο ριλπιβιρινη hcl και δισοπροξιλικη φουμαρικη τενοφοβιρη
EA201500366A1 (ru) Применение 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей в фармацевтических композициях в качестве нейроретинопротектора
PH12019501070A1 (en) Sustained-release dosage forms of ruxolitinib
CY1116711T1 (el) Νεοι ανθελονοσιακοι παραγοντες
TR201200215A2 (tr) Geliştirilmiş farmasötik formülasyonlar.
TH171908A (th) องค์ประกอบบำบัดที่ประกอบรวมด้วย ริลพิวิรีน HCL (rilpivirine HCL) และ เทโนโฟเวียร์ ไดโซพรอกซิล ฟิวมาเรต (tenofovir disoproxil fumarate)
TR201200212A2 (tr) Risedronat içeren geliştirilmiş formülasyonlar.